When: Price sustained above key levels with volume confirmation

Then: Proceed only if lower fills are in place to manage tail risk

Wait for entry at 6.20-6.35 (near 50 SMA); reduce first tranche to 25% at 6.20-6.35; eliminate breakout tranche; flush tranche only with reversal confirmation; position size at 1.5%; stop at 6.01.

• MACD histogram deteriorated from +2.13 to -2.26 in one session; MACD is 5-8 sessions from crossing zero, which triggers institutional selling
• Wide-range reversal day (39 dollar intraday range, 6% of price, 2.5x ATR) is redistribution, not buyer absorption; ATR expanded 16% in two weeks
• Forward P/E of 23.8 vs trailing 35.3 embeds execution risk; 73.4 billion in goodwill (54.8B) and intangibles (18.6B) equals 65% of total assets from 13B M&A
• 10.5% revenue growth is partially purchased via M&A; goodwill grew 7.6B and intangibles 3.5B in one year; organic vs. reported growth not disclosed
• Beta of 0.87 at 5%+ 10-year yield is growth stock pricing with defensive veneer, not true defensive pricing (which should be 15-20x)
• Rising rate risk: 5.5% 10-year possible by year-end per Polymarket (44% odds); long-duration earnings compression threatens multiple
• No news catalyst = asymmetric downside to Q3 earnings in late October; single miss on organic growth, FY2026 guidance, or margins will be punished
• Current close at 6.56 likely prevents first tranche fill (50% at 6.40-6.52), creating position concentration risk with same stop exposure
• Revised plan: 25% first tranche at 6.20-6.35 (near 50 SMA at 6.21), stop 3-5% below entry vs. 5-9% currently; 1.5% position size

→ vs aggressive: MACD argument: MACD line at 14.96 is irrelevant; rate of change is negative with histogram at -2.26, and 5-8 sessions until zero cross means waiting for confirmation, not buying ahead of it

→ vs aggressive: Wide-range reversal: Close at 6.52 is not bullish absorption; 6% intraday range with no news is institutional redistribution; next session typically follows through lower, not continuation higher

→ vs aggressive: Valuation argument: Forward P/E of 23.8 ignores goodwill of 54.8B and intangibles of 18.6B (65% of assets); 10% M&A miss overstates earnings and expands multiple to 26+

→ vs aggressive: Macro argument: TMO at 35x trailing is growth pricing, not defensive; cannot be a hedge against the rate environment that compresses its multiple; true hedge is cash and short-duration credit

→ vs aggressive: News dead zone: Absence of news is absence of catalyst, not bullish; only direction for next catalyst is negative with Q3 earnings binary ahead

→ vs aggressive: Blended risk reward: If stock runs without filling first tranche, 50% position is chased into deteriorating momentum; if tranches fill, buying into confirmed downtrend before thesis validation

BUY with modified tranche allocation: 35% first tranche at 640-652, 30% second tranche at 621-635 with momentum confirmation, 15% breakout tranche above 700 with MACD positive cross, 20% flush tranche at 601 with reversal candle confirmation; 1.5% portfolio allocation; stop at 601

• MACD line remains positive at 14.96 but histogram expanded to downside for 5 consecutive sessions indicating deteriorating momentum
• Price is 5.7% above the 50 SMA at 621 but histogram suggests trend weakening
• Goodwill stands at 54.8 billion with intangibles at 18.6 billion creating M&A integration exposure
• Trailing twelve month free cash flow is 6.24 billion providing capacity to absorb integration costs
• Beta of 0.877 with defensive compounder characteristics provides partial but not full macro hedge
• Polymarket pricing 96% odds of no Fed cuts in 2026 suggests sustained high yield environment
• TMO at 35 times trailing earnings with long-duration equity characteristics in 5%+ yield environment creates multiple compression risk
• Q3 2026 earnings print in late October is key catalyst for organic versus reported growth disclosure
• Original stop at 601 is below lower Bollinger band representing statistical oversold level
• A 615 stop would get taken out on routine volatility around the 50 SMA
• Even a 10% miss on forward EPS still leaves TMO at 25 times forward earnings

→ vs aggressive: Blended risk reward math (2.5 to 1 upside at 635-640) only works if every tranche fills; path dependency creates tail risk if TMO breaks out above 700 without filling second tranche

→ vs aggressive: Macro hedge contradiction: claiming TMO is defensive hedge against tech fragility while TMO is priced for flawless execution in same tape; multiple compression risk if yields push to 5.5%

→ vs aggressive: MACD being 5-8 sessions from crossing zero should not be dismissed; buying largest position exposure exactly when indicator races toward zero cross

→ vs aggressive: Building plan on spreadsheet that assumes tranches fill on command; markets don't fill tranches on schedule

→ vs aggressive: Aggressive position sizing at upper end of 1.5-2.0% not justified despite asymmetric opportunity due to multiple compression tail risk

→ vs conservative: Eliminating breakout tranche entirely throws away asymmetric upside that makes original plan valuable; breakout above 700 with confirmed MACD and RSI is highest expected value scenario

→ vs conservative: M&A integration risk overstated; TMO has been serial acquirer for over decade with real FCF capacity; treating M&A as binary pass/fail is incorrect framing

→ vs conservative: Demand for organic versus reported growth disclosure before entry is stall tactic; perfect information historically arrives after the move not before

→ vs conservative: Tightening stop to 615 is too tight; would be taken out on routine 50 SMA volatility forcing worse re-entry after setup confirms

→ vs conservative: Capping exposure effectively avoids the name entirely rather than position sizing for bounded macro risk